Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.

de la Rubia JE, Drehmer E, Platero JL, Benlloch M, Caplliure-Llopis J, Villaron-Casales C, de Bernardo N, AlarcÓn J, Fuente C, Carrera S, Sancho D, GarcÍa-Pardo P, Pascual R, JuÁrez M, Cuerda-Ballester M, Forner A, Sancho-Castillo S, Barrios C, Obrador E, Marchio P, Salvador R, Holmes HE, Dellinger RW, Guarente L, Estrela JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):115-122. doi: 10.1080/21678421.2018.1536152. Epub 2019 Jan 22.

PMID:
30668199
2.

Oxidative stress and antioxidants in the pathophysiology of malignant melanoma.

Obrador E, Liu-Smith F, Dellinger RW, Salvador R, Meyskens FL, Estrela JM.

Biol Chem. 2019 Apr 24;400(5):589-612. doi: 10.1515/hsz-2018-0327. Review.

3.

Erratum: Author Correction: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study.

Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E.

NPJ Aging Mech Dis. 2018 Aug 20;4:8. doi: 10.1038/s41514-018-0027-1. eCollection 2018.

4.

12-Hydroxyeicosatetraenoic acid levels are increased in actinic keratoses and squamous cell carcinoma.

Laquer V, Dellinger RW, Mannering I, Garcia AG, Abraham V, Pavlis J, Liu-Smith F, De Feraudy S, Meyskens FL Jr, Kelly KM.

J Am Acad Dermatol. 2018 Dec;79(6):1152-1153. doi: 10.1016/j.jaad.2018.05.1251. Epub 2018 Jun 11. No abstract available.

PMID:
29902547
5.

Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study.

Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E.

NPJ Aging Mech Dis. 2017 Nov 24;3:17. doi: 10.1038/s41514-017-0016-9. eCollection 2017. Erratum in: NPJ Aging Mech Dis. 2018 Aug 20;4:8.

6.

Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy.

Estrela JM, Mena S, Obrador E, Benlloch M, Castellano G, Salvador R, Dellinger RW.

J Med Chem. 2017 Dec 14;60(23):9413-9436. doi: 10.1021/acs.jmedchem.6b01026. Epub 2017 Jul 11.

PMID:
28654265
7.

Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration.

Mukherjee S, Chellappa K, Moffitt A, Ndungu J, Dellinger RW, Davis JG, Agarwal B, Baur JA.

Hepatology. 2017 Feb;65(2):616-630. doi: 10.1002/hep.28912. Epub 2016 Dec 24. Erratum in: Hepatology. 2017 Apr;65(4):1427.

8.

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.

Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C.

Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948.

9.

Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle.

Frederick DW, Loro E, Liu L, Davila A Jr, Chellappa K, Silverman IM, Quinn WJ 3rd, Gosai SJ, Tichy ED, Davis JG, Mourkioti F, Gregory BD, Dellinger RW, Redpath P, Migaud ME, Nakamaru-Ogiso E, Rabinowitz JD, Khurana TS, Baur JA.

Cell Metab. 2016 Aug 9;24(2):269-82. doi: 10.1016/j.cmet.2016.07.005.

10.

Detection of Total UDP-Glucuronosyltransferase (UGT) Activity in Melanoma Cells.

Dellinger RW, Meyskens FL Jr.

Methods Mol Biol. 2016 Jan 20. [Epub ahead of print]

PMID:
26786882
11.

Continuing to illuminate the mechanisms underlying UV-mediated melanomagenesis.

Dellinger RW, Liu-Smith F, Meyskens FL Jr.

J Photochem Photobiol B. 2014 Sep 5;138:317-23. doi: 10.1016/j.jphotobiol.2014.06.006. Epub 2014 Jun 20. Review.

12.

Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences.

Dellinger RW, Garcia AM, Meyskens FL Jr.

Drug Metab Pharmacokinet. 2014;29(2):112-9. Epub 2013 Aug 20.

13.

Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.

Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL Jr.

PLoS One. 2012;7(10):e47696. doi: 10.1371/journal.pone.0047696. Epub 2012 Oct 22.

14.

Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.

Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P.

Pharmacogenet Genomics. 2010 Oct;20(10):575-85. doi: 10.1097/FPC.0b013e32833b04af.

16.

Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.

Olson KC, Dellinger RW, Zhong Q, Sun D, Amin S, Spratt TE, Lazarus P.

Drug Metab Dispos. 2009 Oct;37(10):1999-2007. doi: 10.1124/dmd.108.024596. Epub 2009 Jul 9.

17.

Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P.

Cancer Res. 2009 Apr 1;69(7):2981-9. doi: 10.1158/0008-5472.CAN-08-4143. Epub 2009 Mar 24.

18.

Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines.

Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P.

Pharmacogenet Genomics. 2008 Mar;18(3):181-91. doi: 10.1097/FPC.0b013e3282f4dbdd.

PMID:
18300939
19.

Glucuronidation of tobacco-specific nitrosamines by UGT2B10.

Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P.

Drug Metab Dispos. 2008 May;36(5):824-30. doi: 10.1124/dmd.107.019406. Epub 2008 Jan 31.

20.

Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism.

Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P.

Cancer Res. 2007 Oct 1;67(19):9024-9.

21.

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.

Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P.

Drug Metab Dispos. 2007 Nov;35(11):2006-14. Epub 2007 Jul 30.

PMID:
17664247
22.

Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10.

Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P.

Carcinogenesis. 2007 Nov;28(11):2412-8. Epub 2007 Jul 17.

PMID:
17638922
23.

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P.

Breast Cancer Res. 2006;8(4):R50.

24.
25.

NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint.

Dellinger RW, Karjian PL, Neuteboom ST.

Anticancer Drugs. 2003 Jul;14(6):449-55.

PMID:
12853888
26.

Human Spy1 promotes survival of mammalian cells following DNA damage.

Barnes EA, Porter LA, Lenormand JL, Dellinger RW, Donoghue DJ.

Cancer Res. 2003 Jul 1;63(13):3701-7.

27.

Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2.

Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ.

J Cell Biol. 2002 Apr 29;157(3):357-66. Epub 2002 Apr 29.

28.

Speedy: a novel cell cycle regulator of the G2/M transition.

Lenormand JL, Dellinger RW, Knudsen KE, Subramani S, Donoghue DJ.

EMBO J. 1999 Apr 1;18(7):1869-77.

Supplemental Content

Loading ...
Support Center